Alzheimer's Disease Classification Research Articles

A multi-omics study to monitor senescence-associated secretory phenotypes of Alzheimer's disease.

Alzheimer's disease (AD) is characterized by the progressive degeneration and damage of neurons in the brain. However, developing an accurate diagnostic assay using blood samples remains a challenge in clinic practice. The aim of this study was to explore senescence-associated secretory phenotypes (SASPs) in peripheral blood using mass spectrometry based multi-omics approach and to establish diagnostic assays for AD. This retrospective study included 88 participants, consisting of 29 AD patients and 59 cognitively normal (CN) individuals. Plasma and serum samples were examined using high-resolution mass spectrometry to identify proteomic and metabolomic profiles. Receiver operating characteristic (ROC) analysis was employed to screen biomarkers with diagnostic potential. K-nearest neighbors (KNN) algorithm was utilized to construct a multi-dimensional model for distinguishing AD from CN. Proteomics analysis revealed upregulation of five plasma proteins in AD, including RNA helicase aquarius (AQR), zinc finger protein 587B (ZNF587B), C-reactive protein (CRP), fibronectin (FN1), and serum amyloid A-1 protein (SAA1), indicating their potential for AD classification. Interestingly, KNN-based three-dimensional model, comprising AQR, ZNF587B, and CRP, demonstrated its high accuracy in AD recognition, with evaluation possibilities of 0.941, 1.000, and 1.000 for the training, testing, and validation datasets, respectively. Besides, metabolomics analysis suggested elevated levels of serum phenylacetylglutamine (PAGIn) in AD. The multi-omics outcomes highlighted the significance of the SASPs, specifically AQR, ZNF587B, CRP, and PAGIn, in terms of their potential for diagnosing AD and suggested neuronal aging-associated pathophysiology.

Deep Convolutional Curvelet Transform- Based MRI Approach for Early Detection of ALZHEIMER' S Disease

Image processing is a technique for applying various procedures to a picture in order to improve it or extract some relevant information from it. It is a kind of signal processing where the input is an image and the output may either be another picture or features or characteristics related to that image. Image processing is one of the technologies that is currently expanding quickly. It is a primary subject of research in both the engineering and computer science fields. For dementia, Alzheimer's disease (AD) is the most prevalent kind. It often shows itself as a steadily declining memory and cognitive function, which makes it difficult for the affected person to live independently and has a significant negative influence on both the affected person and society. At the moment, AD diagnosis depends on medical history analysis, blood testing, behavior analysis, brain imaging, and cognitive testing. But because these processes are arbitrary and uneven, it is difficult to provide a precise forecast for the early phases of AD challenging. A dynamic dual-graph fusion convolutional network is suggested in this paper to enhance the accuracy of Alzheimer's disease (AD) diagnosis. The key contributions of the paper are as follows: The proposed architecture can dynamically adjust the graph structure for GCN to produce better diagnosis outcomes by learning the optimal underlying latent graph, propose a novel dynamic GCN architecture, which is an end-to-end pipeline for diagnosing AD, incorporate feature graph learning and dynamic graph learning, giving those useful features of subjects more weight while reducing the weights of other noise features. Experiments show that our approach achieves great classification results in AD diagnosis while offering flexibility and stability. This project is implemented for the Alzheimer disease classification using Graph convolutional network architecture like CNN with LSTM layer and fit the model in the training and testing and deploy the model for getting the test image output and then compare the accuracy of the model for getting the most perfect model for medical image classification and get the accuracy of CNN- LSTM layer with 98%.

Performance Evaluation of Deep, Shallow and Ensemble Machine Learning Methods for the Automated Classification of Alzheimer's Disease.

Artificial intelligence (AI)-based approaches are crucial in computer-aided diagnosis (CAD) for various medical applications. Their ability to quickly and accurately learn from complex data is remarkable. Deep learning (DL) models have shown promising results in accurately classifying Alzheimer's disease (AD) and its related cognitive states, Early Mild Cognitive Impairment (EMCI) and Late Mild Cognitive Impairment (LMCI), along with the healthy conditions known as Cognitively Normal (CN). This offers valuable insights into disease progression and diagnosis. However, certain traditional machine learning (ML) classifiers perform equally well or even better than DL models, requiring less training data. This is particularly valuable in CAD in situations with limited labeled datasets. In this paper, we propose an ensemble classifier based on ML models for magnetic resonance imaging (MRI) data, which achieved an impressive accuracy of 96.52%. This represents a 3-5% improvement over the best individual classifier. We evaluated popular ML classifiers for AD classification under both data-scarce and data-rich conditions using the Alzheimer's Disease Neuroimaging Initiative and Open Access Series of Imaging Studies datasets. By comparing the results to state-of-the-art CNN-centric DL algorithms, we gain insights into the strengths and weaknesses of each approach. This work will help users to select the most suitable algorithm for AD classification based on data availability.

Convolutional Neural Networks for Early Detection and Classification of Alzheimer's disease from MRI Images

This ponder examines the early discovery and classification of Alzheimer's Illness (AD) from MRI pictures utilizing Convolutional Neural Systems (CNNs) and other machine learning strategies. The investigation compares the execution of CNNs with conventional calculations such as Support Vector Machine (SVM), Random Forest (RF), and Extreme Gradient Boosting (XGBoost) on a dataset comprising MRI filters from Ad patients and sound controls. Results illustrate that CNNs accomplish prevalent precision (92%), affectability (90%), specificity (94%), and zone beneath the ROC bend (AUC) of 0.96 compared to SVM, RF, and XGBoost. The ponder highlights the potential of profound learning approaches, especially CNNs, in precisely distinguishing Ad pathology from MRI looks, encouraging early determination and intercession. This investigation contributes to the developing body of writing on the application of counterfeit insights in therapeutic imaging and underscores the significance of leveraging progressed computational procedures for handling complex neurological clutters. The discoveries hold a guarantee for progressing quiet results and healthcare administration within the field of neuroimaging and personalized medication.

Application of Convolutional Neural Networks for Early Detection and Classification of Alzheimer's disease from MRI Images

This study investigates the application of convolutional neural networks (CNNs) and traditional machine learning algorithms for the early detection and classification of Alzheimer's disease (AD) using brain Magnetic Resonance Imaging (MRI) data. We compare the performance of CNNs with Support Vector Machines (SVM), Random Forest (RF), and Gradient Boosting Machines (GBM) on a dataset comprising MRI images from AD patients and healthy controls. Results show that CNNs achieved the highest accuracy (90.2%) and area under the receiver operating characteristic curve (AUC-ROC) of 0.95, outperforming SVM, RF, and GBM. The CNN model also exhibited high sensitivity (87.5%) and specificity (92.6%) in distinguishing between AD patients and healthy controls. These findings highlight the effectiveness of CNN-based approaches in leveraging raw MRI images for accurate and early detection of AD.

Exploring Deep Learning Models for Accurate Alzheimer's Disease Classification based on MRI Imaging

INTRODUCTION: Alzheimer's disease (AD), a complex neurodegenerative condition, presents significant challenges in early and accurate diagnosis. Early prediction of AD severity holds the potential for improved patient care and timely interventions. This research investigates the use of deep learning methodologies to forecast AD severity utilizing data extracted from Magnetic Resonance Imaging (MRI) scans.
 OBJECTIVES: This study aims to explore the efficacy of deep learning models in predicting the severity of Alzheimer's disease using MRI data. Traditional diagnostic methods for AD, primarily reliant on cognitive assessments, often lead to late-stage detection. MRI scans offer a non-invasive means to examine brain structure and detect pathological changes associated with AD. However, manual interpretation of these scans is labor-intensive and subject to variability.
 METHODS: Various deep learning models, including Convolutional Neural Networks (CNNs) and advanced architectures like DenseNet, VGG16, ResNet50, MobileNet, AlexNet, and Xception, are explored for MRI scan analysis. The performance of these models in predicting AD severity is assessed and compared. Deep learning models autonomously learn hierarchical features from the data, potentially recognizing intricate patterns associated with different AD stages that may be overlooked in manual analysis.
 RESULTS: The study evaluates the performance of different deep learning models in predicting AD severity using MRI scans. The results highlight the efficacy of these models in capturing subtle patterns indicative of AD progression. Moreover, the comparison underscores the strengths and limitations of each model, aiding in the selection of appropriate methodologies for AD prognosis.
 CONCLUSION: This research contributes to the growing field of AI-driven healthcare by showcasing the potential of deep learning in revolutionizing AD diagnosis and prognosis. The findings emphasize the importance of leveraging advanced technologies, such as deep learning, to enhance the accuracy and timeliness of AD diagnosis. However, challenges remain, including the need for large, annotated datasets, model interpretability, and integration into clinical workflows. Continued efforts in this area hold promise for improving the management of AD and ultimately enhancing patient outcomes.

HyperTMO: a trusted multi-omics integration framework based on hypergraph convolutional network for patient classification.

The rapid development of high-throughput biomedical technologies can provide researchers with detailed multi-omics data. The multi-omics integrated analysis approach based on machine learning contributes a more comprehensive perspective to human disease research. However, there are still significant challenges in representing single-omics data and integrating multi-omics information. This paper presents HyperTMO, a Trusted Multi-Omics integration framework based on Hypergraph convolutional network for patient classification. HyperTMO constructs hypergraph structures to represent the association between samples in single-omics data, then evidence extraction is performed by hypergraph convolutional network, and multi-omics information is integrated at an evidence level. Lastly, we experimentally demonstrate that HyperTMO outperforms other state-of-the-art methods in breast cancer subtype classification and Alzheimer's disease classification tasks using multi-omics data from TCGA (BRCA) and ROSMAP datasets. Importantly, HyperTMO is the first attempt to integrate hypergraph structure, evidence theory, and multi-omics integration for patient classification. Its accurate and robust properties bring great potential for applications in clinical diagnosis. HyperTMO and datasets are publicly available at https://github.com/ippousyuga/HyperTMO. Supplementary data are available at Bioinformatics online.

Exploring Deep Learning Models for Accurate Alzheimer's Disease Classification based on MRI Imaging

INTRODUCTION: Alzheimer's disease (AD), a complex neurodegenerative condition, presents significant challenges in early and accurate diagnosis. Early prediction of AD severity holds the potential for improved patient care and timely interventions. This research investigates the use of deep learning methodologies to forecast AD severity utilizing data extracted from Magnetic Resonance Imaging (MRI) scans.
 OBJECTIVES: This study aims to explore the efficacy of deep learning models in predicting the severity of Alzheimer's disease using MRI data. Traditional diagnostic methods for AD, primarily reliant on cognitive assessments, often lead to late-stage detection. MRI scans offer a non-invasive means to examine brain structure and detect pathological changes associated with AD. However, manual interpretation of these scans is labor-intensive and subject to variability.
 METHODS: Various deep learning models, including Convolutional Neural Networks (CNNs) and advanced architectures like DenseNet, VGG16, ResNet50, MobileNet, AlexNet, and Xception, are explored for MRI scan analysis. The performance of these models in predicting AD severity is assessed and compared. Deep learning models autonomously learn hierarchical features from the data, potentially recognizing intricate patterns associated with different AD stages that may be overlooked in manual analysis.
 RESULTS: The study evaluates the performance of different deep learning models in predicting AD severity using MRI scans. The results highlight the efficacy of these models in capturing subtle patterns indicative of AD progression. Moreover, the comparison underscores the strengths and limitations of each model, aiding in the selection of appropriate methodologies for AD prognosis.
 CONCLUSION: This research contributes to the growing field of AI-driven healthcare by showcasing the potential of deep learning in revolutionizing AD diagnosis and prognosis. The findings emphasize the importance of leveraging advanced technologies, such as deep learning, to enhance the accuracy and timeliness of AD diagnosis. However, challenges remain, including the need for large annotated datasets, model interpretability, and integration into clinical workflows. Continued efforts in this area hold promise for improving the management of AD and ultimately enhancing patient outcomes.

Effective classification of alzheimer disease based on image tractography framework utilizing GM-ABC-NN

A progressive neurological disorder that leads to memory loss as well as cognitive decline is called Alzheimer’s Disease (AD). Grounded on various factors like symptoms, biomarkers, or disease stages, the classification of AD is done. Yet, the prevailing techniques pose challenges in capturing accurate AD, which results in misdiagnosis or delayed treatment. To overcome these issues, an effective framework for the classification of AD based on image tractography using several algorithms is proposed in this article. Primarily, the dataset comprising AD images undergoes image transformation. Then, to enhance the MRI image quality, the transformed images are pre-processed using Block Matching 3D Filtering (BM3D) and Contrast Limited Adaptive Histogram Equalization (CLAHE) algorithms. Afterward, image tractography followed by brain tissue segmentation is done utilizing the Cauchy-Steiner Weighted Fuzzy C Means (CauSt-FCM) algorithm. Then, by utilizing the Cosine Non-Negative Kernel Regression (CosNNK) algorithm, graph construction is done. Lastly, for the feature selection and validation process, the Premature Singer Archerfish Hunting Optimizer (PreS-AHO) algorithm and Analysis of Variance (ANOVA) analysis are used. Thereafter, the AD stages are classified by using the Gaussian Mixture Alpha-Beta Convolutional Neural Network (GM-ABC-NN) algorithm, The proposed system attains superior accuracy (97.56%), precision (97.55%), and recall (97.57%).

Improving the Learning Performance of Client’s Local Distribution in Cyclic Federated Learning

Cyclic federated learning based on distribution information sharing and knowledge distillation (CFL_DS_KD) aims to address the challenges of non-iid data distribution and reduce communication requirements. However, when client data is extremely heterogeneous and scarce, it becomes challenging for clients to fully learn the distribution of local data using GANs, thereby affecting the overall model performance. To overcome this limitation, we propose a transfer learning approach where clients first pretrain their generators on a source domain and then fine-tune them on their local datasets. Our results on the classification of Alzheimer’s disease demonstrate that this method effectively improves client distribution learning performance and enhances the overall model performance.

A joint autoencoder and classifier deep neural network for AD and MCI classification

AbstractIn this article, we present a new approach to distinguish progressive mild cognitively impaired (pMCI) subjects, who eventually develop Alzheimer's disease (AD) from stable MCI (sMCI) subjects whose situation does not deteriorate into AD. The proposed approach combines the discriminating capabilities of classifiers and representation learning capacities of autoencoders into a unified architecture, and is hence termed as joint autoencoder and classifier deep neural network (JACDNN). JACDNN employs a single classifier and multiple autoencoders that are trained together to perform pattern classification. The classifier in JACDNN is trained using standard approaches to distinguish between subject from different classes using the binary cross entropy loss. The autoencoders in JACDNN, regularizes individual layers in the network used for classification to learn representations useful for reconstructing a given input. The performance of JACDNN has been evaluated on several machine learning problems pertaining to dementia, namely AD versus cognitively normal (CN) subjects, AD versus sMCI, CN versus pMCI, and pMCI versus sMCI. These problems are targeted using two datasets. The first dataset consist of gray matter (GM) features of subjects and the second dataset consist of combination of GM and white matter (WM) features. It is observed that better classification results are obtained when the classifier is built on GM and WM as compared with GM features alone. Performance comparison of JACDNN with other existing approaches has been conducted for these problems. The results clearly indicate that JACDNN performs better than other existing approaches for these problems.

Feature Detection Based on Imaging and Genetic Data Using Multi-Kernel Support Vector Machine–Apriori Model

Alzheimer’s disease (AD) is a significant neurological disorder characterized by progressive cognitive decline and memory loss. One essential task is understanding the molecular mechanisms underlying brain disorders of AD. Detecting biomarkers that contribute significantly to the classification of AD is an effective means to accomplish this essential task. However, most machine learning methods used to detect AD biomarkers require lengthy training and are unable to rapidly and effectively detect AD biomarkers. To detect biomarkers for AD accurately and efficiently, we proposed a novel approach using the Multi-Kernel Support Vector Machine (SVM) with Apriori algorithm to mine strongly associated feature sets from functional magnetic resonance imaging (fMRI) and gene expression profiles. Firstly, we downloaded the imaging data and genetic data of 121 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and transformed gene sequences into labeled sequences by encoding the four types of bases (A, T, C, and G) into distinct labels. Subsequently, we extracted the first 130 temporal sequences of brain regions and employed Pearson correlation analysis to construct “brain region gene pairs”. The integration of these data allowed us to explore the correlations between genes and brain regions. To improve classification accuracy and feature selection, we applied the Apriori algorithm to the multi-kernel SVM, dynamically building feature combinations and continuously validating classification results. By iteratively generating frequent itemsets, we obtained important brain region gene pairs. Experimental results show the effectiveness of our proposed approach. The Multi-Kernel SVM with Apriori model achieves an accuracy of 92.9%, precision of 95%, and an F1 score of 95% in classifying brain region-gene pairs within the AD–Late mild cognitive impairment (AD-LMCI) group. The amygdala, BIN1, RPN2, and IL15 associated with AD have been identified and demonstrate potential in identifying potential pathogenic factors of AD. The selected brain regions and associated genes may serve as valuable biomarkers for early AD diagnosis and better understanding of the disease’s molecular mechanisms. The integration of fMRI and gene data using the Multi-Kernel SVM–Apriori model holds great potential for advancing our knowledge of brain function and the genetic basis of neurological disorders. This approach provides a valuable tool for neuroscientists and researchers in the field of genomics and brain imaging studies.

A novel CNN architecture for accurate early detection and classification of Alzheimer’s disease using MRI data

Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder that requires accurate diagnosis for effective management and treatment. In this article, we propose an architecture for a convolutional neural network (CNN) that utilizes magnetic resonance imaging (MRI) data from the Alzheimer’s disease Neuroimaging Initiative (ADNI) dataset to categorize AD. The network employs two separate CNN models, each with distinct filter sizes and pooling layers, which are concatenated in a classification layer. The multi-class problem is addressed across three, four, and five categories. The proposed CNN architecture achieves exceptional accuracies of 99.43%, 99.57%, and 99.13%, respectively. These high accuracies demonstrate the efficacy of the network in capturing and discerning relevant features from MRI images, enabling precise classification of AD subtypes and stages. The network architecture leverages the hierarchical nature of convolutional layers, pooling layers, and fully connected layers to extract both local and global patterns from the data, facilitating accurate discrimination between different AD categories. Accurate classification of AD carries significant clinical implications, including early detection, personalized treatment planning, disease monitoring, and prognostic assessment. The reported accuracy underscores the potential of the proposed CNN architecture to assist medical professionals and researchers in making precise and informed judgments regarding AD patients.

Using blood transcriptome analysis for Alzheimer's disease diagnosis and patient stratification.

Blood protein biomarkers demonstrate potential for Alzheimer's disease (AD) diagnosis. Limited studies examine the molecular changes in AD blood cells. Bulk RNA-sequencing of blood cells was performed on AD patients of Chinese descent (n=214 and 26 in the discovery and validation cohorts, respectively) with normal controls (n=208 and 38 in the discovery and validation cohorts, respectively). Weighted gene co-expression network analysis (WGCNA) and deconvolution analysis identified AD-associated gene modules and blood cell types. Regression and unsupervised clustering analysis identified AD-associated genes, gene modules, cell types, and established AD classification models. WGCNA on differentially expressed genes revealed 15 gene modules, with 6 accurately classifying AD (areas under the receiver operating characteristics curve [auROCs]>0.90). These modules stratified AD patients into subgroups with distinct disease states. Cell-type deconvolution analysis identified specific blood cell types potentially associated with AD pathogenesis. This study highlights the potential of blood transcriptome for AD diagnosis, patient stratification, and mechanistic studies. We comprehensively analyze the blood transcriptomes of a well-characterized Alzheimer's disease cohort to identify genes, gene modules, pathways, and specific blood cells associated with the disease. Blood transcriptome analysis accurately classifies and stratifies patients with Alzheimer's disease, with some gene modules achieving classification accuracy comparable to that of the plasma ATN biomarkers. Immune-associated pathways and immune cells, such as neutrophils, have potential roles in the pathogenesis and progression of Alzheimer's disease.

Enabling uncertainty estimation in neural networks through weight perturbation for improved Alzheimer's disease classification.

The willingness to trust predictions formulated by automatic algorithms is key in a wide range of domains. However, a vast number of deep architectures are only able to formulate predictions without associated uncertainty. In this study, we propose a method to convert a standard neural network into a Bayesian neural network and estimate the variability of predictions by sampling different networks similar to the original one at each forward pass. We combine our method with a tunable rejection-based approach that employs only the fraction of the data, i.e., the share that the model can classify with an uncertainty below a user-set threshold. We test our model in a large cohort of brain images from patients with Alzheimer's disease and healthy controls, discriminating the former and latter classes based on morphometric images exclusively. We demonstrate how combining estimated uncertainty with a rejection-based approach increases classification accuracy from 0.86 to 0.95 while retaining 75% of the test set. In addition, the model can select the cases to be recommended for, e.g., expert human evaluation due to excessive uncertainty. Importantly, our framework circumvents additional workload during the training phase by using our network "turned into Bayesian" to implicitly investigate the loss landscape in the neighborhood of each test sample in order to determine the reliability of the predictions. We believe that being able to estimate the uncertainty of a prediction, along with tools that can modulate the behavior of the network to a degree of confidence that the user is informed about (and comfortable with), can represent a crucial step in the direction of user compliance and easier integration of deep learning tools into everyday tasks currently performed by human operators.

Classification of Alzheimer's disease: application of a transfer learning deep Q-network method.

Early diagnosis is crucial to slowing the progression of Alzheimer's disease (AD), so it is urgent to find an effective diagnostic method for AD. This study intended to investigate whether the transfer learning approach of deep Q-network (DQN) could effectively distinguish AD patients using local metrics of resting-state functional magnetic resonance imaging (rs-fMRI) as features. This study included 1310 subjects from the Consortium for Reliability and Reproducibility (CoRR) and 50 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) GO/2. The amplitude of low-frequency fluctuation (ALFF), fractional ALFF (fALFF) and percent amplitude of fluctuation (PerAF) were extracted as features using the Power 264 atlas. Based on gender bias in AD, we searched for transferable similar parts between the CoRR feature matrix and the ADNI feature matrix, resulting in the CoRR similar feature matrix served as the source domain and the ADNI similar feature matrix served as the target domain. A DQN classifier was pre-trained in the source domain and transferred to the target domain. Finally, the transferred DQN classifier was used to classify AD and healthy controls (HC). A permutation test was performed. The DQN transfer learning achieved a classification accuracy of 86.66% (p < 0.01), recall of 83.33% and precision of 83.33%. The findings suggested that the transfer learning approach using DQN could be an effective way to distinguish AD from HC. It also revealed the potential value of local brain activity in AD clinical diagnosis.

An effectual recommendation model using hybrid learning models for early detection of Alzheimer’s disease

Alzheimer’s disease (AD) is a neurodegenerative disorder that affects millions of individuals worldwide, causing progressive cognitive decline. Early prediction and diagnosis the AD accurately is crucial for effective intervention and treatment. In this study, we propose a comprehensive framework for AD prediction using various techniques, including preprocessing and denoising with Multilayer Perceptron (MLP) and Ant Colony Optimization (ACO), segmentation using U-Net, and classification with Spatial Pyramid Pooling Network (SPPNet). Furthermore, we employ Convolutional Neural Network (CNN) with SPPNet for training and develop a chatbot for recommendation based on MRI data input. The preprocessing and denoising techniques play a vital role in enhancing the quality of the input data. MLP is utilized for preprocessing, where it effectively handles feature extraction and noise reduction. ACO is employed for denoising, optimizing the data to improve the signal-to-noise ratio, and enhancing the overall performance of subsequent stages. For accurate segmentation of brain regions, we employ the U-Net architecture, which has shown remarkable success in medical image segmentation tasks. U-Net effectively identifies the regions of interest, aiding in subsequent classification stages. The classification phase utilizes SPPNet, a deep learning model known for its ability to capture spatial information at multiple scales. SPPNet extracts features from segmented brain regions, enabling robust classification of AD and non-AD cases. To enhance the training process, we employ CNN with SPPNet, leveraging the power of convolutional layers to capture intricate patterns and improve predictive accuracy. The CNN-SPPNet model is trained on a large dataset of MRI scans, enabling it to learn complex representations and make accurate predictions. Hence the proposed work can be integrated with a chatbot that takes MRI data as input and provides recommendations based on the predicted AD probability. Experimental evaluation shows that the combination of preprocessing, denoising, segmentation, and classification offers a comprehensive solution for accurate and efficient AD diagnosis and management.

Exploring the Value of MRI Measurement of Hippocampal Volume for Predicting the Occurrence and Progression of Alzheimer's Disease Based on Artificial Intelligence Deep Learning Technology and Evidence-Based Medicine Meta-Analysis.

Alzheimer's disease (AD), a major dementia cause, lacks effective treatment. MRI-based hippocampal volume measurement using artificial intelligence offers new insights into early diagnosis and intervention in AD progression. This study, involving 483 AD patients, 756 patients with mild cognitive impairment (MCI), and 968 normal controls (NC), investigated the predictive capability of MRI-based hippocampus volume measurements for AD risk using artificial intelligence and evidence-based medicine. Utilizing data from ADNI and OASIS-brains databases, three convolutional neural networks (InceptionResNetv2, Densenet169, and SEResNet50) were employed for automated AD classification based on structural MRI imaging. A multitask deep learning model and a densely connected 3D convolutional network were utilized. Additionally, a systematic meta-analysis explored the value of MRI-based hippocampal volume measurement in predicting AD occurrence and progression, drawing on 23 eligible articles from PubMed and Embase databases. InceptionResNetv2 outperformed other networks, achieving 99.75% accuracy and 100% AUC for AD-NC classification and 99.16% accuracy and 100% AUC for MCI-NC classification. Notably, at a 512×512 size, InceptionResNetv2 demonstrated a classification accuracy of 94.29% and an AUC of 98% for AD-NC and 97.31% accuracy and 98% AUC for MCI-NC. The study concludes that MRI-based hippocampal volume changes effectively predict AD onset and progression, facilitating early intervention and prevention.

A Review of Deep Learning Approaches for Early Diagnosis of Alzheimer's Disease

Alzheimer's disease (AD), one of the major neurodegenerative diseases, has become the most common cause of dementia problems. Up to now, there is a lack of effective targeted therapeutic drugs and effective treatment modalities to stop the progression of the disease. With the continuous development of computer technology, the use of computer-aided diagnostic technology tools for AD early classification studies will provide clinicians with important assistance. Deep learning-based Alzheimer's disease (AD) imaging classification has become a current research hotspot. In this paper, we first describe the commonly used publicly available datasets in the AD imaging classification task; then introduce the commonly used deep learning classification models for AD diagnosis; secondly, we compare the studies that target different biomarkers of the subjects and the use of unimodal or a combination of different modalities for the early classification of AD; and finally, The challenges of AD classification are summarized and future research directions are proposed.

Early Diagnosing and Transformation Prediction of Alzheimer's Disease Using Multi-Scaled Self-Attention Network on Structural MRI Images with Occlusion Sensitivity Analysis.

Structural magnetic resonance imaging (sMRI) is vital for early Alzheimer's disease (AD) diagnosis, though confirming specific biomarkers remains challenging. Our proposed Multi-Scale Self-Attention Network (MUSAN) enhances classification of cognitively normal (CN) and AD individuals, distinguishing stable (sMCI) from progressive mild cognitive impairment (pMCI). This study leverages AD structural atrophy properties to achieve precise AD classification, combining different scales of brain region features. The ultimate goal is an interpretable algorithm for this method. The MUSAN takes whole-brain sMRI as input, enabling automatic extraction of brain region features and modeling of correlations between different scales of brain regions, and achieves personalized disease interpretation of brain regions. Furthermore, we also employed an occlusion sensitivity algorithm to localize and visualize brain regions sensitive to disease. Our method is applied to ADNI-1, ADNI-2, and ADNI-3, and achieves high performance on the classification of CN from AD with accuracy (0.93), specificity (0.82), sensitivity (0.96), and area under curve (AUC) (0.95), as well as notable performance on the distinguish of sMCI from pMCI with accuracy (0.85), specificity (0.84), sensitivity (0.74), and AUC (0.86). Our sensitivity masking algorithm identified key regions in distinguishing CN from AD: hippocampus, amygdala, and vermis. Moreover, cingulum, pallidum, and inferior frontal gyrus are crucial for sMCI and pMCI discrimination. These discoveries align with existing literature, confirming the dependability of our model in AD research. Our method provides an effective AD diagnostic and conversion prediction method. The occlusion sensitivity algorithm enhances deep learning interpretability, bolstering AD research reliability.